MTOR and neoplasm: FGF19-FGFR4 signalling activates several pathways, including extracellular regulated protein kinases(ERK), jun N-terminal kinase (JNK), phosphoinositide 3-kinase (PI3K), mammalian target of rapamycin (mTOR) and others, which are closely related to tumour progression [28, 45, 46].